Table 4.
Main characteristics of responders and non-responders in mutations sub-analysis.
| Patients and disease characteristics | Response, n = 23 (35.4%) | Non-response, n = 42 (64.6%) | p Value |
|---|---|---|---|
| Age (median) [p25–p75] | 76 years [71–83] | 76 years [65–80] | 0.422 |
| Gender | 23 | 76 | 0.200 |
| Male | 9 (39.1%) | 24 (57.1%) | |
| Female | 14 (60.9%) | 18 (42.9%) | |
| WHO 2008 | 21 | 41 | 0.042 |
| <5% blasts | 20 (95.2%) | 30 (73.2%) | |
| RCUD | 2 (9.5%) | 2 (4.9%) | |
| RARS | 9 (42.9%) | 9 (22%) | |
| RCMD | 8 (38.1%) | 17 (41.5%) | |
| MDS-U | 1 (4.35%) | 2 (4.9%) | |
| >5% blasts and CMML | 1 (4.8%) | 6 (14.5%) | |
| RAEB-1 | 0 (0%) | 1 (2.4%) | |
| RAEB-2 | 0 (0%) | 1 (2.4%) | |
| CMML | 1 (4.3%) | 3 (7.3%) | |
| Others MDS/MPN | 0 (0%) | 1 (2.4%) | |
| MDS with del(5q) | 0 (0%) | 5 (12.2%) | |
| Not available | 2 | 1 | |
| IPSS | 23 | 40 | 0.781 |
| Low | 17 (73.9%) | 28 (70%) | |
| Intermediate-1 | 6 (26.1%) | 12 (30%) | |
| Not available | 0 | 2 | |
| IPSS-R | 23 | 37 | 0.157 |
| Very low | 9 (39.1%) | 8 (20.5%) | |
| Low | 13 (56.5%) | 25 (64.1%) | |
| Intermediate | 1 (4.3%) | 6 (15.3%) | |
| Not available | 0 | 5 | |
| Hemoglobin (median) [p25–p75] | 9.8 g/dl [9.3–10.4] | 9.2 g/dl [8.1–10.1] | 0.033 |
| Hemoglobin | 23 | 42 | 0.188 |
| >8 g/dl | 21 (91.3%) | 32 (76.2%) | |
| <8 g/dl | 2 (8.7%) | 10 (23.8%) | |
| Platelets (median) [p25–p75] | 270 × 109/l [196–453] | 230 × 109/l [185–315] | 0.244 |
| Leucocytes (median) [p25–p75] | 5.76 × 109/l [3.9–8.4] | 4.62 × 109/l [3.4–6.6] | 0.144 |
| EPO (median) [p25–p75] | 47.9 U/l [22–118] | 110.5 U/l [41–172] | 0.027 |
| EPO 100 | 18 | 26 | 0.124 |
| <100 U/l | 13 (72.2%) | 12 (46.2%) | |
| ⩾100 U/l | 5 (21.7%) | 14 (33.3%) | |
| Not available | 5 | 16 | |
| EPO 200 | 18 | 26 | 0.211 |
| <200 U/l | 17 (94.4%) | 20 (76.9%) | |
| ⩾200 U/l | 1 (5.6%) | 6 (23.1%) | |
| Not available | 5 | 16 | |
| Ferritin (median) [p25–p75] | 449 ng/ml [256–621] | 368 ng/ml [p25–p75] | 0.652 |
| Ferritin | 18 | 35 | 1.000 |
| <500 ng/ml | 12 (66.7%) | 24 (68.6%) | |
| >500 ng/ml | 6 (33.3%) | 11 (31.4%) | |
| Not available | 5 | 7 | |
| Transfusion dependency | 23 | 42 | <0.001 |
| Yes | 11 (47.8%) | 39 (92.9%) | |
| No | 12 (52.5%) | 3 (7.1%) | |
| Cytogenetics | 23 | 39 | 0.034 |
| Normal | 21 (91.3%) | 26 (66.7%) | |
| Abnormal | 2 (8.7%) | 13 (33.3%) | |
| Not available | 0 | 3 | |
| Mutated genes | 23 | 42 | 0.248 |
| <3 | 19 (82.6%) | 28 (66.7%) | |
| ⩾3 | 4 (17.4%) | 14 (33.3%) |
CMML, chronic myelomonocytic leukemia; EPO, erythropoietin; IPSS, International Prognostic Scoring System; IPSS-R, IPPS Revised; MDS/MPN, myelodisplastic syndrome/myeloproliferative neoplasm; MDS-U, myelodysplastic syndrome unclassifiable; RAEB, refractory anemia with excess blasts; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization.